IQOS Clear Cover

IQOS Clear Cover

IQOS Clear Cover Features and Benefits

The IQOS clear cover is easy to use and does not require any maintenance. The product meets the statutory requirements for MRTP and PMI’s MRTP Assessment Program evaluated the IQOS clear cover’s performance in a number of biological systems. The results from this study show that the IQOS clear cover is more efficient than the smoke-free alternative, and that smoking cessation can be significantly reduced.
The PMI scientific assessment program’s results are consistent, coherent, and biologically relevant. The findings indicate that the IQOS clear cover can help smokers transition from cigarettes. The results of these studies are consistent with the IQOS brand, and are comparable to those of cigarette products. Further, this study also shows that IQOS has reduced the health risks associated with cigarettes. Therefore, PMI expects it to continue to be approved for a variety of uses.
The FDA approved IQOS in June 2015. The product’s safety and effectiveness will be evaluated as part of the Post-Market Assessment program. This study will confirm the IQOS clear cover’s ability to reduce tobacco-related harm and benefit the population. Several studies have shown that the product has been shown to have significant behavioral intentions to use, as demonstrated by the fact that an extensive proportion of adult smokers switched from traditional cigarettes to IQOS.

The IQOS clear cover has been shown to reduce the harm caused by smoking by up to 94 percent. The FDA approved IQOS in May 2016. The IQOS product is USB-charged, has a port to roll tobacco, and a clear plastic casing that resembles a short cigarette. While this product may look similar to a regular cigarette, its aesthetic is more reminiscent of an asthma inhaler. There are no smoking signs, no flame, and no smoke. Users exhale a ghostly wisp, which makes it seem like an electronic cigarette.

PMI conducts post-market assessment activities in countries where IQOS is commercialized. During this program, it identifies adverse events and other risks. The PMI medical experts use information from external sources to assess the safety and effectiveness of IQOS. The PMI uses the results of these studies to further improve the safety of the product. This study also shows the effectiveness of the IQOS clear cover in reducing combustible cigarette costs.
In addition to testing the IQOS, PMI is developing an analysis infrastructure. It will monitor discussions related to the IQOS and the various risks associated with it. It will also examine the impact on the public’s health, including the perceived risk of IQOS on smokers’ lives. Its purpose is to create a safer alternative to cigarettes and vaping. The data will also help PMI evaluate the effectiveness of the IQOS on its marketing strategy.